1.77
price down icon2.75%   -0.05
pre-market  Vorhandelsmarkt:  1.77  
loading
Schlusskurs vom Vortag:
$1.82
Offen:
$1.88
24-Stunden-Volumen:
392.12K
Relative Volume:
0.24
Marktkapitalisierung:
$4.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.91M
KGV:
-0.5429
EPS:
-3.26
Netto-Cashflow:
$-6.14M
1W Leistung:
-14.08%
1M Leistung:
-5.35%
6M Leistung:
-37.89%
1J Leistung:
-55.92%
1-Tages-Spanne:
Value
$1.61
$1.88
1-Wochen-Bereich:
Value
$1.61
$2.34
52-Wochen-Spanne:
Value
$1.15
$23.80

Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile

Name
Firmenname
Galmed Pharmaceuticals Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
6
Name
Twitter
@GalmedPharma
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
GLMD's Discussions on Twitter

Vergleichen Sie GLMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GLMD
Galmed Pharmaceuticals Ltd
1.77 4.65M 0 -6.91M -6.14M -3.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-05-22 Herabstufung B. Riley FBR Buy → Neutral
2020-02-04 Eingeleitet Craig Hallum Buy
2020-01-30 Fortgesetzt Cantor Fitzgerald Overweight
2019-12-02 Eingeleitet Canaccord Genuity Buy
2018-12-12 Eingeleitet B. Riley FBR Buy
2018-08-02 Bestätigt Maxim Group Buy
2018-07-13 Eingeleitet Stifel Buy
2018-07-12 Eingeleitet Cantor Fitzgerald Overweight
2018-06-12 Bestätigt H.C. Wainwright Buy
2018-03-15 Hochstufung Maxim Group Hold → Buy
2018-02-14 Herabstufung Maxim Group Buy → Hold
2018-02-12 Bestätigt H.C. Wainwright Buy
2017-11-15 Eingeleitet ROTH Capital Buy
2017-08-08 Bestätigt H.C. Wainwright Buy
2017-07-31 Bestätigt Maxim Group Buy
2016-08-01 Bestätigt Maxim Group Buy
2016-07-06 Fortgesetzt ROTH Capital Buy
2016-03-28 Fortgesetzt H.C. Wainwright Buy
2015-06-23 Eingeleitet H.C. Wainwright Buy
2015-05-06 Eingeleitet Sun Trust Rbsn Humphrey Buy
Alle ansehen

Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten

pulisher
Jul 22, 2025

Galmed Pharmaceuticals Ltd. Stock Analysis and ForecastRapid portfolio appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Galmed Pharmaceuticals Ltd. stock priceMassive stock growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Galmed Pharmaceuticals Ltd. a good long term investmentTurbocharged investment results - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Galmed Pharmaceuticals Ltd. stockMarket-beating performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

The Role of News and Events in Galmed Pharmaceuticals Ltd Inc. (GLMD) Price Performance - investchronicle.com

Jul 21, 2025
pulisher
Jul 20, 2025

Why India’s Pharmaceutical Stocks Are on the Rise High Accuracy Trade SignalsRapid market gains - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 19, 2025

Solara Active Pharma Sciences Limited (SOLARAPP)’s Trend in 2025Free Stock Market Forecast Reports - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

PLAB Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Galmed Pharmaceuticals Ltd. stock price move sharplyFree Insider Trading Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Galmed Pharmaceuticals Ltd. stock attracts strong analyst attentionSafe and Scalable Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Galmed Pharmaceuticals Ltd. stock performs during market volatilitySteady Profit Stock Forecasts - Newser

Jul 15, 2025
pulisher
Jun 03, 2025

Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire

Jun 03, 2025
pulisher
May 27, 2025

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential - TipRanks

May 27, 2025
pulisher
May 27, 2025

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - Longview News-Journal

May 27, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Sell - Defense World

May 24, 2025
pulisher
May 23, 2025

Galmed Pharmaceuticals: Q1 Earnings Snapshot - New Haven Register

May 23, 2025
pulisher
May 22, 2025

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology - TipRanks

May 22, 2025
pulisher
May 22, 2025

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

May 22, 2025
pulisher
May 15, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World

May 15, 2025
pulisher
May 14, 2025

Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models - TipRanks

May 14, 2025
pulisher
May 14, 2025

Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramc - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramchol in Treating PSC | GLMD Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models - PR Newswire

May 13, 2025
pulisher
May 10, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 10, 2025
pulisher
May 08, 2025

Galmed Pharmaceuticals Ltd’s Market Journey: Closing Weak at 1.29, Down -11.64 - DWinneX

May 08, 2025
pulisher
May 07, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World

May 07, 2025
pulisher
May 07, 2025

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’ By Stocktwits - Investing.com India

May 07, 2025
pulisher
May 06, 2025

GLMD Advances Cancer Treatment with Promising Aramchol Results | GLMD Stock News - GuruFocus

May 06, 2025

Finanzdaten der Galmed Pharmaceuticals Ltd-Aktie (GLMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):